Corporate Citizenship Report

At Biogen, our mission is clear: we are pioneers in neuroscience. Our focus on neuroscience and our deep scientific expertise make us leaders in the research and development of medicines with the potential to transform neuroscience and to benefit society.

That leadership is demonstrated through our commitment to positively impact our communities, to inspire the next generation of scientists, to solve social and environmental challenges and to create a diverse and inclusive workforce that thrives professionally and personally.

Our mission and our impact in the community exemplify our leadership and are vital to the growth of Biogen.

 

2017 Highlights

  • 43% of positions at the director level and above are held by women
  • Four consecutive years ‘Best Place to Work’ for LGBT equality in the U.S.
  • More than 2,600 employees in 26 countries supported more than 60 volunteer projects as part of the 2017 Care Deeply Day
  • $6.2 million in community grants and Biogen Foundation employee matching gifts in 2017
  • 5,133 students, along with 524 employee volunteers, participated in our Community Lab programs in 2017 to learn more about science and technology
  • 75% reduction in operational carbon intensity since 2006
  • Carbon-neutral company since 2014
  • Engaged with 10 suppliers representing 36% of our supply chain total to reduce GHG emissions in 2017

 

About the Report

The 2017 Corporate Citizenship Report contains data from calendar year 2017. In some instances, we include information on initiatives or activities that may have begun in 2017, but have continued into 2018.

This report was prepared in accordance with the GRI G4 Guidelines “core” option. Please refer to the GRI Index to see which GRI material aspects and relevant indicators are reported. Also, see below for how we track our efforts in alignment with the U.N. Sustainable Development Goals (SDGs).

 

GRI Report

For the 2017 report, we are using the 2016 GRI materiality assessment, the most recent GRI materiality assessment available. In this analysis, we identified 18 issues for further attention.

After reviewing the entire list, a set of tier one GRI priorities was agreed upon for immediate attention, including: access to treatments, investments in R&D to ensure a robust pipeline and improved patient outcomes. Throughout this 2017 Corporate Citizenship Report, we explain how Biogen is addressing these issues and measuring performance.

The process to develop the 2016 GRI materiality assessment involved external stakeholder interviews, desk research to establish the broader sustainability context, an internal visioning workshop to prioritize and validate the issues and external stakeholder meetings to review the findings and gather feedback. We intend to conduct a new GRI materiality assessment for the 2018 Corporate Citizenship Report.